A study of an experimental drug in patients with metastatic castration resistant prostate cancer

UVA Tracking #
Principal Investigator
Robert Dreicer
Jennifer Drake
Contact Email
Contact Phone
Official Trial Title
A Phase 1/2, open-label, dose escalation and cohort expansion clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARV-110 in patients with metastatic castration-resistant prostate cancer
Study Description

The UVA Cancer Center seeks adult males ages 18 and over with metastatic castration resistant prostate cancer (mCRPC) for a clinical trial.

The purpose of this study is to evaluate an experimental drug, which is a protein degrader (ARV-110), in patients with mCRPC. Disease response and good and bad effects of the drug will be studied as part of this trial.

Study specific tests will be provided at no cost to you.


No Compensation; Reimbursement: Up to $175 per night for hotel stay.